Regulator of cell cycle RGCC

Regulator of cell cycle RGCC (RGCC) also known as response gene to complement 32 protein (RGC-32) is a protein that in humans is encoded by the RGCC gene.

RGCC
Identifiers
Aliases	RGCC, C13orf15, RGC-32, RGC32, bA157L14.2, regulator of cell cycle
External IDs	OMIM: 610077; MGI: 1913464; HomoloGene: 8544; GeneCards: RGCC; OMA:RGCC - orthologs
Gene location (Human) Chr. Chromosome 13 (human) Band 13q14.11 Start 41,457,550 bp End 41,470,871 bp
Gene location (Mouse) Chr. Chromosome 14 (mouse) Band 14|14 D3 Start 79,526,196 bp End 79,539,085 bp
RNA expression pattern Bgee Human Mouse (ortholog) Top expressed in decidua right lung upper lobe of left lung lower lobe of lung parotid gland olfactory bulb tibial nerve synovial joint amniotic fluid trabecular bone Top expressed in intercostal muscle submandibular gland tunica adventitia of aorta white adipose tissue left lung lobe subcutaneous adipose tissue brown adipose tissue tibiofemoral joint thymus digastric muscle More reference expression data BioGPS More reference expression data
Gene ontology Molecular function R-SMAD binding protein kinase activator activity protein binding protein kinase binding Cellular component cytoplasm centrosome microtubule organizing center cytoskeleton nucleus cytosol nucleolus Biological process positive regulation of collagen biosynthetic process negative regulation of blood vessel endothelial cell migration negative regulation of cell-cell adhesion mediated by cadherin complement activation positive regulation of extracellular matrix assembly positive regulation of DNA-binding transcription factor activity negative regulation of mitotic cell cycle phase transition positive regulation of epithelial to mesenchymal transition positive regulation of extracellular matrix constituent secretion regulation of cell cycle negative regulation of endothelial cell proliferation positive regulation of endothelial cell apoptotic process positive regulation of gene expression positive regulation of DNA biosynthetic process negative regulation of angiogenesis cell cycle fibroblast activation negative regulation of exit from mitosis positive regulation of mitotic nuclear division cellular response to hypoxia negative regulation of fibroblast growth factor production positive regulation of stress fiber assembly positive regulation of transcription by RNA polymerase II negative regulation of cell population proliferation activation of protein kinase activity DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest positive regulation of cyclin-dependent protein serine/threonine kinase activity positive regulation of G1/S transition of mitotic cell cycle Sources:Amigo / QuickGO
Orthologs Species Human Mouse Entrez 28984 66214 Ensembl ENSG00000102760 ENSMUSG00000022018 UniProt Q9H4X1 Q9DBX1 RefSeq (mRNA) NM_014059 NM_025427 RefSeq (protein) NP_054778 NP_079703 Location (UCSC) Chr 13: 41.46 – 41.47 Mb Chr 14: 79.53 – 79.54 Mb PubMed search
Wikidata
View/Edit Human View/Edit Mouse

Function

This gene is thought to regulate cell cycle progression. It is induced by p53 in response to DNA damage, or by sublytic levels of complement system proteins that result in activation of the cell cycle. The encoded protein localizes to the cytoplasm during interphase and to centrosomes during mitosis. The protein forms a complex with polo-like kinase 1. The protein also translocates to the nucleus in response to treatment with complement system proteins, and can associate with and increase the kinase activity of cell division cycle 2 protein. In different assays and cell types, overexpression of this protein has been shown to activate or suppress cell cycle progression.

Further reading

• Fosbrink M, Niculescu F, Rus H (2005). "The role of c5b-9 terminal complement complex in activation of the cell cycle and transcription". Immunol. Res. 31 (1): 37–46. doi:10.1385/IR:31:1:37. PMID 15591621. S2CID 25558055.
• Bonaldo MF, Lennon G, Soares MB (1997). "Normalization and subtraction: two approaches to facilitate gene discovery". Genome Res. 6 (9): 791–806. doi:10.1101/gr.6.9.791. PMID 8889548.
• Badea TC, Niculescu FI, Soane L, et al. (1998). "Molecular cloning and characterization of RGC-32, a novel gene induced by complement activation in oligodendrocytes". J. Biol. Chem. 273 (41): 26977–81. doi:10.1074/jbc.273.41.26977. PMID 9756947.
• Badea T, Niculescu F, Soane L, et al. (2002). "RGC-32 increases p34CDC2 kinase activity and entry of aortic smooth muscle cells into S-phase". J. Biol. Chem. 277 (1): 502–8. doi:10.1074/jbc.M109354200. PMID 11687586.
• Ota T, Suzuki Y, Nishikawa T, et al. (2004). "Complete sequencing and characterization of 21,243 full-length human cDNAs". Nat. Genet. 36 (1): 40–5. doi:10.1038/ng1285. PMID 14702039.
• Fosbrink M, Cudrici C, Niculescu F, et al. (2005). "Overexpression of RGC-32 in colon cancer and other tumors". Exp. Mol. Pathol. 78 (2): 116–22. doi:10.1016/j.yexmp.2004.11.001. PMID 15713436.
• Tanaka T, Takada H, Nomura A, et al. (2005). "Distinct gene expression patterns of peripheral blood cells in hyper-IgE syndrome". Clin. Exp. Immunol. 140 (3): 524–31. doi:10.1111/j.1365-2249.2005.02805.x. PMC 1809394. PMID 15932515.
• Olsen JV, Blagoev B, Gnad F, et al. (2006). "Global, in vivo, and site-specific phosphorylation dynamics in signaling networks". Cell. 127 (3): 635–48. doi:10.1016/j.cell.2006.09.026. PMID 17081983.